Daybue Guidance Looks Achievable for Acadia, Neuren -- Market Talk

0011 GMT - Acadia Pharmaceuticals' target of $370 million-$420 million net sales of its Daybue treatment for Retts Syndrome looks achievable to Jefferies, despite a small miss in 1Q. In a research not

WSJ08:12

Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million

Neuren Pharmaceuticals (ASX:NEU) partner Acadia Pharmaceuticals (NASDAQ:ACAD) posted Q1 net sales of its DAYBUE treatment in the US of $75.9 million, below its guidance of $76 million to $82 million,

MT Newswires05:24

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m.

Businesswire04:58

ACADIA Pharmaceuticals | 10-Q: Quarterly report

Futu News03:44 · Announcements

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript

Yahoo Finance03:29

ACADIA Pharmaceuticals Price Target Cut to $27.00/Share From $33.00 by HC Wainwright & Co.

ACADIA Pharmaceuticals Price Target Cut to $27.00/Share From $33.00 by HC Wainwright & Co.

Dow Jones02:29